SCHEMBL5623622

SCHEMBL5623622

NC(=O)C(c1ccccc1)N(Cc1ccc(C(=O)O)cc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 15/20 0.57
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
PSEN1 P49768 1/20 0.51
PSEN2 P49810 1/20 0.51
APH1B Q8WW43 1/20 0.51
NCSTN Q92542 1/20 0.51
APH1A Q96BI3 1/20 0.51
PSENEN Q9NZ42 1/20 0.51
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CXCR3 P49682 1/20 0.49
PTGES O14684 2/20 0.47
TAS2R8 Q9NYW2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117430 0.92 TAS2R14 (0.62) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5117441 0.92 TAS2R14 (0.62) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5122191 0.89 TAS2R14 (0.53) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5116607 0.89 TAS2R14 (0.64) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5116620 0.89 TAS2R14 (0.64) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5122060 0.87 KDM4E (0.53) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL5122055 0.87 KDM4E (0.53) TAS2R14PSEN1PSEN2APH1BNCSTN
SCHEMBL5128796 0.85 PSEN1 (0.54) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5128798 0.85 PSEN1 (0.54) TAS2R14MEN1KMT2APSEN1PSEN2
SCHEMBL5124198 0.84 PSEN1 (0.54) TAS2R14MEN1KMT2APSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7163942-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2007-01-16 US disclosed
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PSEN1, APP, PSEN2 TAS2R14 1257/4885MEN1 751/4885KMT2A 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.